Experimental drug tested for boys with Muscle-Wasting disease
NCT ID NCT06079736
Summary
This study tested an experimental drug called PGN-EDO51 in boys with Duchenne muscular dystrophy who have a specific genetic mutation. The main goal was to check if the drug is safe and how the body processes it when given through an IV over time. Researchers also measured whether the treatment increased dystrophin protein levels in muscles, which is crucial for muscle function in this condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
British Columbia Children's Hospital
Vancouver, British Columbia, V6H1G9, Canada
-
CHU de Québec
Québec, Quebec, G1V4G2, Canada
-
Children's Hospital of Eastern Ontario (CHEO)
Ottawa, Ontario, K1H8L1, Canada
-
Stan Cassidy Centre for Rehabilitation
Fredericton, New Brunswick, E3B0C7, Canada
-
The Hospital for Sick Children (SickKids)
Toronto, Ontario, M5G0A4, Canada
Conditions
Explore the condition pages connected to this study.